AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Neuronetics' Revenue Surges 132% YoY, Positions as Neurohealth Leader with FDA Clearance for Adolescent TMS Therapy.
ByAinvest
Tuesday, Sep 2, 2025 3:55 am ET1min read
Neuronetics, Inc. (NASDAQ:STIM) reported Q2 2025 revenue of $38.1 million, a 132% YoY increase, driven by Greenbrook integration and expansion to 95 clinics. The company is expanding its SPRAVATO program and gained FDA clearance for NeuroStar in adolescents, establishing it as a first-line therapy. Revenue for fiscal 2025 is projected between $149 million and $155 million, with positive cash flow from operations anticipated by Q4 2025. The business continues investing in growth and talent, navigating challenges in profitability and stock volatility.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet